CRISPRMED25 Speakers (early confirmation)

Scientific Conference (virtual, April 7, 2025 | in-person, April 8-11, 2025)

Keynote Speaker: Virginijus Šikšnys, Prof., Ph.D., Head of Department, Vilnius University, Lithuania

Patient Advocate: Jimi Olaghere is a CASGEVY recipient who has developed a keen interest in the advancements of cell and gene therapies, since his transformative participation in the groundbreaking clinical trial. Jimi is passionate about the positive impact that these therapies can have on patients in need and has become a staunch advocate for increased accessibility of gene therapies for sickle cell disease patients worldwide. At CRISPRMED25, Jimi will share his story about living with sickle cell disease, before and after treatment with the recently approved CRISPR therapy CASGEVY.

• Alessia Cavazza, Ass. Prof., Group Leader, Infection, Immunity & Inflammation Department at University College London's Great Ormond Street Institute of Child Health, England
• Alvin Luk, Co-Founder, CEO, and Head of Medical at HuidaGene Therapeutics, Inc., US
• Anna Cereseto, Prof., Vice-Director, Centre for Integrative Biology (CIBIO), University of Trento, Italy
• Annarita Miccio, Group Leader, Ph.D., Imagine Institute of Genetic Diseases, France
• Attila Sebe, MD, PhD (Paul-Ehrlich-Institute, Federal Institute for Vaccines and Biomedicines, Division of Haematology, Cell and Gene Therapy, Germany)
• Ayal Hendel, Principal Investigator and Group Leader, Bar-Ilan University, Israel
• Blair Madison, Ph.D., Chief Scientific Officer, Gene Therapy at Poseida Therapeutics, US
• Dolça Rogers, Ph.D., ATMP topic lead, Pharmaceutical Quality Office, European Medicines Agency (EMA), Netherlands
• Emma Wang, Ph.D., CTO, YolTech Therapeutics, China
• Gerald Schwank, Prof., Ph.D., University of Zürich, Switzerland
• Guillermo Montoya, Prof., Research Director and Group Leader at the Protein Structure and Function program at CPR, University of Copenhagen, Denmark
• Jacob Corn, Prof., Ph.D., ETH Zürich, Switzerland
• Jakob Giehm Mikkelsen, Prof., Ph.D., Aarhus University, Denmark
• Jakob Nilsson, Prof., Ph.D., Danish Cancer Institute, Copenhagen, Denmark
• Julian Grünewald, Ass. Prof., MD, Ph.D., Technical University of Munich, Germany
• Karim Benabdel Lah El Khlanji, Senior Scientist at the GENyO Pfizer-University of Granada-Junta de Andalucia Center for Genomics and Oncological Research in Granada, Spain, GeneHumdi Action Chair
• Kiana Aran, Associate Professor of Bioengineering and Medicine, University of California San Diego, US
• Marcello Maresca, Senior Director, Genome Engineering Team, AstraZeneca, Sweden
• Matthew Porteus, Prof., MD, Ph.D., Stanford Medicine, US
• Özcan Met, Ph.D., Associate Professor and Head of Cell Therapy Unit at the National Center for Cancer Immune Therapy (CCIT-DK) at Herlev University Hospital and DTU HealthTech, Denmark
• Raffaella Di Micco, Group Leader, Ph.D., SR-TIGET, Italy
• Rasmus O. Bak, Ass. Prof. and Group Leader, Aarhus University, Denmark
• Suk See De Ravin, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), US
• Thorsten Stafforst, Ph.D., Professor at Interfaculty Institute of Biochemistry at the University of Tuebingen, Germany.
• William H. Peranteau, MD, Surgeon and Professor, University of Pennsylvania/Children’s Hospital of Philadelphia, US
• Xavier Duportet, Ph.D., CEO and Co-founder, Eligo Biosciences
• TBD, Life Edit Therapeutics, US
• TBD, ReCode Therapeutics, US

Startup-Investor Event "Invest in Future CRISPR Medicine | Develop Future Medicine" (in-person, April 8, 2025)

• Michael Krohn, Co-CEO, Akribion Genomics, Germany
• Jiawei Lee, Co-founder and Chief Business Officer, QUiCKR Bio, US
• Jan Nelis, Project Lead and Co-Founder, Ariya Bio, Switzerland
• Michael Jackson, Venture Capitalist

Go to the Official CRISPRMED25 website to see the full updated list